Biobeat
PrivateLast Round
Series B
Dec 30, 2025
Total Funding Raised
$58M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Biobeat operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series B round in December 2025.
Biobeat is a medical technology company that develops wearable remote patient monitoring devices designed to measure vital signs using wireless, non-invasive, and medical-grade technology.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Telemedicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biobeat Comparables
Compare Biobeat with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioIntelliSense | 91% | |
| VitalConnect | 84% | |
| Vivalink | 83% |
For institutional investors. Book with your work email.
Biobeat Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 30, 2025 | ||||
| Series A | Mar 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biobeat Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ally Bridge Group | Series B |
| OrbiMed | Series B |
| Menomadin Foundation | Series A |
| Elevage Medical Technologies | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
Added Nuvance Health, a healthcare provider, as a customer.
- May 6, 2026
Added National Jewish, a mid-market healthcare company, as a customer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 6, 2026
On Oct 6th '26, Biobeat announces plans to host an expert panel session and exhibit at the American Heart Association's Hypertension Scientific Sessions 2026, featuring discussion of cuffless 24-hour ambulatory blood pressure monitoring and new clinical data.
For institutional investors. Book with your work email.
Biobeat Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biobeat's valuation, stock price, and market status.
Is Biobeat a public or private company?
Biobeat is a private company.
What is the current stock price of Biobeat?
Biobeat is a private company, so its shares have no public market price. Caplight tracks Biobeat's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biobeat worth (valuation)?
Valuation information for Biobeat is not publicly available.
Can I buy Biobeat stock?
Biobeat shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biobeat's last funding round?
Biobeat's most recent funding round was Series B on December 30, 2025.
Who are the main investors in Biobeat?
Key investors in Biobeat include Ally Bridge Group, OrbiMed, Menomadin Foundation, Elevage Medical Technologies.
Will Biobeat IPO soon?
No public IPO plans have been announced for Biobeat.
How can I track Biobeat secondary market activity?
Caplight tracks bids, offers, and trades in Biobeat's shares on secondary markets.